SNCA and Parkinson disease: We previously demonstrated that Nilotinib promotes autophagic clearance of neurotoxic proteins and improves motor and cognitive symptoms in several models of neurodegeneration without evidence of increased inflammation.6, 7, 9, 11, 12, 13, 57, 58, 59 Measurement of CSF alpha‐synuclein with other PD‐related biomarkers like TREM2 and DA metabolism may validate the utility of CSF and/or plasma alpha‐synuclein as a biomarker, not for the diagnosis or progression of PD, but for specific drug effects like Nilotinib.